Holen Sie sich die Stockscreener-App
4.72
6.43%
0.285
Handel nachbörslich:
4.67
-0.05
-1.06%
Schlusskurs vom Vortag:
$4.435
Offen:
$4.67
24-Stunden-Volumen:
82,410
Relative Volume:
0.27
Marktkapitalisierung:
$7.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.58M
KGV:
-4.1043
EPS:
-1.15
Netto-Cashflow:
$-9.80M
1W Leistung:
-6.53%
1M Leistung:
-50.11%
6M Leistung:
-68.82%
1J Leistung:
-87.58%
1-Tages-Spanne:
$4.5101
$4.9399
1-Wochen-Bereich:
$3.80
$5.1082
52-Wochen-Spanne:
$3.80
$47.80
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Firmenname
Acurx Pharmaceuticals Inc
Sektor
Branche
Telefon
917-533-1469
Adresse
259 LIBERTY AVENUE, STATEN ISLAND
Vergleichen Sie ACXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
4.72 | 6.82M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2025 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals (NASDAQ:ACXP) Given New $31.00 Price Target at HC Wainwright - Defense World
Key metrics from Acurx Pharmaceuticals Inc.’s quarterly data2025 Growth vs Value & Consistent Income Trade Recommendations - Newser
Will Acurx Pharmaceuticals Inc. continue its uptrendRate Hike & Safe Entry Point Alerts - Newser
Acurx Pharmaceuticals stock price target raised to $31 from $8 at H.C. Wainwright - Investing.com UK
What does recent volatility data suggest for Acurx Pharmaceuticals Inc.Analyst Downgrade & Daily Price Action Insights - Newser
What’s the recovery path for long term holders of Acurx Pharmaceuticals Inc.Layoff News & Verified Momentum Stock Alerts - Newser
Acurx Pharmaceuticals (NASDAQ:ACXP) Price Target Raised to $31.00 at HC Wainwright - Defense World
Acurx Pharmaceuticals Reports Positive Q2 Earnings with Promising Clinical Advances and Strategic Financial Management - AInvest
Acurx Pharmaceuticals Inc (ACXP) Q2 2025 Earnings Call Highlights: Strategic Financial ... By GuruFocus - Investing.com Canada
Does Acurx Pharmaceuticals Inc. fit your quant trading model [2025 Stock Rankings]Real-Time Buy Signal Alerts - Newser
Will Acurx Pharmaceuticals Inc. continue its uptrend [Trade Volume Summary]Free Safe Capital Growth Stock Tips - Newser
Acurx Pharmaceuticals Reports Reduced Losses Amid Ongoing R&D Efforts - TipRanks
Is now a turning point for Acurx Pharmaceuticals Inc.Trend Reversal Watch with Entry Signals - Newser
Chart based exit strategy for Acurx Pharmaceuticals Inc.Share Buyback & Verified Momentum Stock Ideas - Newser
Real time pattern detection on Acurx Pharmaceuticals Inc. stockFree High Conviction Intraday Stock Signals - Newser
What makes Acurx Pharmaceuticals Inc. stock price move sharply2025 Performance Recap & Stepwise Trade Execution Plans - Newser
Will Acurx Pharmaceuticals Inc. stock recover after recent dropFree Low Volatility Stable Growth Picks - Newser
H.C. Wainwright Initiates Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Announces Target Price $31 - 富途牛牛
Acurx Pharmaceuticals Q2 2025: Key Contradictions in Funding, Phase III Trials, and Strategic Partnerships - AInvest
Acurx Pharmaceuticals Q2 Earnings: Cost Controls, New Trial Funding, and Advancements in Ibepazolstat Clinical Program - AInvest
Earnings call transcript: Acurx Pharmaceuticals Q2 2025 misses EPS forecast By Investing.com - Investing.com Canada
Transcript : Acurx Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Acurx Earnings: Net Loss Slashed by Half as Phase 2b Data Published in Lancet Microbe - Stock Titan
How high can Acurx Pharmaceuticals Inc. stock goEntry Opportunity Screener with Confirmation - Newser
Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update - Finansavisen
What’s next for Acurx Pharmaceuticals Inc. stock priceInvestment Timing Strategy with Market Filters - Newser
Is Acurx Pharmaceuticals Inc. trading at a discountLow Float Big Mover Alerts - mustnews.co.kr
Why Acurx Pharmaceuticals Inc. stock attracts strong analyst attentionChart Driven Opportunity Scanner with Alerts - Newser
Can Acurx Pharmaceuticals Inc. rally from current levelsFree Low Risk Picks for Daily Trading - Newser
Intraday pattern recognizer results for Acurx Pharmaceuticals Inc.Sector Rotation Outlook With Historical Summary - Newser
Using R and stats models for Acurx Pharmaceuticals Inc. forecastingFree Step-by-Step Stock Investment Guide - Newser
Sectors Driving Future Growth for Acurx Pharmaceuticals Inc. Stock2-Day Signal Watch with Forecast Outcome - Newser
Is Acurx Pharmaceuticals Inc. gaining market shareLow Risk High Return Picks - sisaissue.com
Developing predictive dashboards with Acurx Pharmaceuticals Inc. dataTop Stock Picks with Forecast Accuracy - Newser
Acurx Pharmaceuticals (ACXP) to Release Earnings on Tuesday - Defense World
How Acurx Pharmaceuticals Inc. stock performs during market volatilityFree Market Surge Signal for Swing Traders - Newser
What risks could impact Acurx Pharmaceuticals Inc. stock performanceChart Pattern Strategy with ROI Focus - Newser
Acurx Pharmaceuticals (NASDAQ:ACXP) Rating Increased to Sell at Wall Street Zen - Defense World
Heatmap analysis for Acurx Pharmaceuticals Inc. and competitorsShort Term Momentum Based Trading Strategy - Newser
Multi asset correlation models including Acurx Pharmaceuticals Inc.Daily Pick Forecast with Entry Zones - Newser
Tools to assess Acurx Pharmaceuticals Inc.’s risk profileFree Entry Plan for Oversold Reversal Stocks - Newser
Finanzdaten der Acurx Pharmaceuticals Inc-Aktie (ACXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):